Search PubMed⌕ Search

Biomedical subjects

R Hansen

Publications and source records attributed to R Hansen.

139 records · Page 8Linked to original sources
PubMed1975

Tuberculosis care in general hospitals: Arizona's experience.

In June 1973 the state of Arizona transferred all in-hospital care of patients with tuberculosis from the State Sanatorium to general hospitals. Eleven general hospitals, 2 extended care facilities, and 30 physicians are under contract; the state pays billed charges after payment from any third-party insurers. Admission to the Tuberculosis Hospitalization Program is controlled by the state and requires real evidence of need for hospital care; there are no residency or indigency requirements. During the first 2 years of the program, 279 patients were admitted for hospital care. The average length of stay was 23.6 days; a marked decrease from the 93-day average in the sanatorium in 1971-1972. Of the 274 patients discharged during the first 2 years, 232 had a final diagnosis of tuberculosis; 105 of these were discharged with sputum smears positive for acid-fast bacilli. Although the cost per patient day was higher than in the sanatorium, the average cost of hospitalization per patient was lower because of the decrease in length of stay. Thirty-five per cent of the patients had some insurance coverage and/or Medicare. An employee skin testing program was required in all hospitals participating in the program. Although there was a 3.5 per cent conversion rate among all hospital employees, there were only 5 converters among employees exposed to patients with tuberculosis under the program. None of the employees was found to have tuberculosis. Of 70 patients with active tuberculosis who have been followed 12 to 24 months, 65 are bacteriologically negative. The general hospital program has been well accepted by patients, physicians, hospitals, and the public.

Adult↗
PubMedDate not supplied

Concomitant adjuvant chemotherapy and radiotherapy for high risk breast cancer patients.

Thirty four patients treated with mastectomy and axillary node dissection for potentially curable breast cancer received a seven month combined adjuvant chemotherapy and radiation therapy program. These patients were considered to be at high risk for recurrence because they had either three or more positive axillary lymph nodes or their primary tumor was greater than 5 cm in diameter. The chemotherapy given at 3-week intervals consisted of cyclophosphamide, 600 mg/m2, Adriamycin 40 mg/m2, and methotrexate 40 mg/m2 during cycles 1 through 3 and 7 through 9. Radiation therapy was administered during cycles 4 through 6 with concomitant administration of 5-fluorouracil 600 mg/m2, vincristine 1.4 mg/m2, and prednisone 40 mg/m2 for 7 days. Median follow up time from initiation of study is 60 months (range 36-93). Seventeen of 34 patients (50%) remain free of recurrent breast cancer. Distant metastases and local-regional recurrence have occurred in 16 (47%) and 4 (12%) patients, respectively. Significant myelosuppression and infections requiring hospitalization were seen in 4 patients, with 1 treatment-related death. Adriamycin-containing chemotherapy and post-operative radiotherapy can thus be combined in an adjuvant treatment program with acceptable toxicity.

Adult↗
PubMedDate not supplied

[Supply of iodine during pregnancy--an inventory in Berlin, Germany].

BACKGROUND: Iodised salt was introduced in Germany in the early 1980s. A nation-wide study in 1996 showed that iodine levels among the population had improved since the introduction of the supplementation. The study did not separately investigate the iodine status of pregnant women. In our prospective study, we used three parameters to assess the iodine levels among pregnant women. PATIENTS AND METHODS: Between October 1999 and February 2000, we asked 109 German-speaking patients seeking prenatal care in our clinic to participate. Following informed consent, we measured goiter volume by ultrasound and collected venous blood (serum) and urine samples. We asked patients about any history of thyroid gland illnesses and about iodine supplementation which is generally given to pregnant patients in Germany. The blood and urine samples were stored at -18 degrees C until measurement. We used the iodine-creatinine-ratio to measure ioduria. Iodine was measured using the Cer-Arsenite-method (Dade-Behring). The thyroglobulin concentration in serum was measured using RIA. RESULTS: The mean iodine-creatinine ratio was 181 +/- 109 microg/g, 20.4 % of the patients had a ratio between 50 and 100 microg/g which is defined as iodine deficiency I degrees (WHO). 8.7 % of the patients had thyreoglobulin levels above the cut-off value of 50 ng/ml. 12.6 % of the patients had a goiter (volume > 18 ml). 58 % of the patients were taking iodine supplements. These patients had significantly higher iodine-creatinine ratio levels (204 microg/g vs. 148 microg/g, P = 0.007) and lower serum thyroglobulin levels (38.4 vs. 34.1 pmol/l, P = 0.06) than non-supplemented patients. CONCLUSIONS: The prevalence of goiter reflects an extended period of iodine deficiency. Using laboratory methods, up to 20.4 % of pregnant women were identified as having an iodine deficiency which indicates the need for a general iodine supplementation during pregnancy.

Adult↗
PubMedDate not supplied

Prevalence and persistence of heparin/platelet factor 4 antibodies in patients with heparin coated and noncoated ventricular assist devices.

Thromboembolism is a major complication in patients with ventricular assist devices (VAD). Anticoagulation with heparin, coumarin, and anti-platelet agents, particularly the development of biocompatible surfaces such as inner pseudo-endothelial layers or a coating with heparin, are intended to reduce these complications. However, the administration of heparin can lead to heparin induced thrombocytopenia type II (HIT II). Predominantly heparin/platelet factor 4 (HPF4) antibodies are responsible for the development of HIT II. The goal of the present investigation was to assess the prevalence of these antibodies in patients with heparin coated and noncoated VADs. Fifty-five patients were enrolled in the investigation. A heparin coated system was implanted in 30 patients, and a noncoated system was implanted in 25 patients. Antibodies were evaluated before, on days 7 and 14, and 3 months after implantation. Testing was performed with the Heparin/Platelet factor 4 enzyme-linked immunosorbent assay (ELISA) (Stago, France). In 40 of the 55 patients, the formation of HPF4 antibodies was observed (73%). In 35 of these patients (88%), HPF4 antibodies were present before surgery. There were no differences between the groups. In 11 patients (equal from both groups), the antibodies disappeared after termination of systemic heparinization. We conclude that in a rather high percentage of patients with VADs HPF4 antibodies are found. This finding may be explained by the repetitive and prolonged exposure of these patients to heparin. Immobilized heparin, as presently used in the carmeda coating, seems not to influence the formation and persistence of HPF4 antibodies. Further studies will have to prove whether HPF4 antibodies contribute to thromboembolic complications in these patients.

Adult↗
PubMedDate not supplied

Reducing blood glucose variability by use of abdominal insulin injection sites.

Virtually all patients with type I diabetes are familiar with inexplicable fluctuations in blood glucose concentration that expose them to both hypoglycemia and hyperglycemia. It is commonly assumed that such fluctuations are due, in large part, to variations in food intake, physical activities, and emotional state. However, substantial day-to-day variation in blood glucose concentration is observed when diet, exercise, emotional state, insulin dosage, and timing of insulin administration are held constant. This suggests that variation in the rate of absorption of insulin from the subcutaneous injection sites may be an important factor causing those fluctuations. Variations in insulin absorption are increased if the anatomic regions used for injections are rotated. A recent study completed at the University of Minnesota Hospital and Clinic indicates that it is inadvisable for type I diabetic subjects to rotate insulin injection regions; rather, insulin injections should be confined to a single anatomic region (usually the abdomen) as this will decrease day-to-day variability in blood glucose concentration. Such a decrease should allow greater precision in adjusting insulin doses, thereby helping achieve good control.

Abdomen↗